Study results shows longer term stability, well tolerated, good news
To summarize, the Phase 3 study of Juxtapid showed continued success in meeting primary endpoints for efficacy over a longer time horizon while keeping the same safety profile as they did at 78 weeks. This shows that longer term use continues to be effective (whereas many medications taper off substantially the longer you use them).
So, continued effectiveness over a longer period of time, stable safety profile (same as before, just now with a longer time horizon), and continued success.
Oh, and one person had to discontinue, who was an alcoholic, but even that provides useful data. Few medications are even remotely tolerated when an excess of alcohol is introduced. So this is no surprise.